Intranasal Corticosteroid For Seasonal Allergic Rhinitis Therapeutics
1. Alvesco patent expiration
Treatment: Method of treating inflammatory conditions; Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. patent claims method for treating a resp...
ALVESCO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5605674 | AZURITY | Medicinal aerosol formulations |
Feb, 2014
(12 years ago) | |
| US5683677 | AZURITY | Medicinal aerosol formulations |
Nov, 2014
(11 years ago) | |
| US6006745 | AZURITY | Device for delivering an aerosol |
Dec, 2016
(9 years ago) | |
| US5775321 | AZURITY | Seal configuration for aerosol canister |
Jul, 2015
(11 years ago) | |
| US6036942 | AZURITY | Seal configuration for aerosol canister |
Apr, 2013
(13 years ago) | |
| US5482934 | AZURITY | Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions |
Oct, 2017
(8 years ago) | |
| US6120752 | AZURITY | Medicinal aerosol products containing formulations of ciclesonide and related steroids |
May, 2018
(8 years ago) | |
| US8371292 | AZURITY | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(1 year, 6 months from now) | |
| US6264923 | AZURITY | Medicinal aerosol formulation of ciclesonide and related compounds |
May, 2018
(8 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 20, 2011 |
| M(M-125) | Dec 17, 2015 |
Drugs and Companies using CICLESONIDE ingredient
NCE-1 date: 20 October, 2010
Market Authorisation Date: 10 January, 2008
Dosage: AEROSOL, METERED
More Information on Dosage
ALVESCO family patents
